MFAP2 is a hub SRIG linking eCAFs, ECM remodeling, and immune escape in GC, which serves as a reliable prognostic and ICI resistance predictor and potential therapeutic target, providing a basis for precision therapy in GC.
Abstract
Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide, with poor prognosis and immune checkpoint inhibitor (ICI) resistance mediated by immune escape. Senescence-related immunosuppressive genes (SRIGs) regulate the tumor microenvironment (TME); however, their hub genes and prognostic value in GC remain unclear. This study aimed to identify hub SRIGs and explore their significance.
Transcriptomic, single-cell RNA sequencing, and spatial transcriptomic data of GC were obtained from The Cancer Genome Atlas and Gene Expression Omnibus databases. Weighted gene co-expression network analysis and Pearson correlation analysis were used to screen for SRIGs. Eight machine learning algorithms identified the hub SRIG, which was validated by RT-qPCR, immunohistochemistry, and clinical samples. Pseudotime trajectory, CellChat, and molecular docking analyses were used to explore the underlying mechanisms and potential drugs. A pan-cancer analysis was used to verify its generalizability.
A senescence-related immunosuppressive signature was constructed, stratifying GC into two subtypes with distinct TME and prognosis. Microfibril-associated protein 2 (MFAP2) was identified as the hub SRIG, significantly upregulated in GC, and an independent prognostic risk factor. It was specifically expressed in extracellular matrix cancer-associated fibroblasts (eCAFs), driving their differentiation and extracellular matrix (ECM) remodeling. MFAP2⁺ eCAFs promoted M2 macrophage polarization via CSF1-CSF1R and C3-C3AR1 axes, mediating immune escape and ICI resistance. AZD4547 and MK-2461 were potential targeted drugs. Pan-cancer analysis confirmed the ubiquitous oncogenic role of MFAP2.
MFAP2 is a hub SRIG linking eCAFs, ECM remodeling, and immune escape in GC. It serves as a reliable prognostic and ICI resistance predictor and potential therapeutic target, providing a basis for precision therapy in GC.
The biological role of VPS45 in hepatocellular carcinoma (HCC) is clarified and, through comprehensive database analyses combined with in vitro experiments, supports its potential as a diagnostic and predictive biomarker for HCC.
Ji-Ming Duan, Wen-Jun Zhao, Na Lv et al.· Journal of Hepatocellular Ca...· 0 citations
Findings suggest that KLK6 overexpression in LUAD is driven in part by promoter hypomethylation and is closely linked to a neutrophil-dominant immunosuppressive microenvironment and may serve as a promising prognostic biomarker and a potential therapeutic target for LUAD.
Ling-Jie Chen, Wen-Bo Zhou, Jiong-Jie Wang et al.· Current Medicinal Chemistry· 0 citations
PRKX drives immune exhaustion in the GC1 subtype by stabilizing PD-L1 through phosphorylation-dependent inhibition of ubiquitination, thereby promoting immune evasion and targeting PRKX represents a potential strategy to overcome resistance to anti-PD-1 therapy.
Qi-Yue Wang, Yin-Qi Chen, Dong-Dong Huang et al.· Journal for ImmunoTherapy of...· 0 citations
PPP1R14B (PP1 regulatory inhibitor subunit 14B) was overexpressed in PCa and associated with poor prognosis, promoting PCa cell proliferation, suppressing apoptosis, and correlating with increased tumor purity but reduced CD8+ T-cell infiltration.
Jie Yang, Chuan Zhou, Wen-Bo Zhang et al.· Journal of Pathology· 0 citations
This study delineates the detailed molecular mechanisms by which the RBP CSTF2 exacerbates malignant progression in BC, offering fresh theoretical insights and potential targets for targeted immunotherapeutic strategies in BC.
Tangxiaoman Wang, Lei Yan, Jia-Li Jiang et al.· Breast Cancer· 0 citations
A validated six-gene signature is proposed that refines prognostic stratification, delineates immunerelevant HCC subtypes and highlights candidate biomarkers for therapeutic selection and mechanistic investigation.
Yu-Xin Liang, Xing Chen, Yuhao Su et al.· Gene· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.